Order Botox® for Clinics

Botox® (onabotulinumtoxinA) is a purified botulinum toxin type A supplied as a sterile, vacuum-dried powder in single-dose vials that are reconstituted before injection. Licensed clinics, hospitals and medical professionals order it for in-office treatment across its FDA-approved therapeutic indications, which include chronic migraine prevention, cervical dystonia, upper and lower limb spasticity, overactive bladder and severe primary axillary hyperhidrosis. Units of this product are specific to this product, so vial strength and reconstitution volume are decisions your team makes before the treatment room is set up.

Vial sizes and unit planning

Botox® vials are shown in 50 Unit and 100 Unit presentations at ordering. Match the vial size to the indication you treat most often and to the number of patients you can realistically treat from one reconstituted vial. Vials are labeled for single-dose use, and the FDA labeling directs that any unused reconstituted product is discarded rather than held for later sessions.

High-unit indications such as limb spasticity or detrusor overactivity usually make a 100 Unit botox vial more practical. Lower-unit work, including axillary hyperhidrosis or smaller focal dystonia protocols, can suit a 50 Unit vial and reduce waste. Many practices stock both so a single delivery covers mixed appointment types in the same week.

Why it matters: Vial size drives both unit cost per patient and the amount of product discarded at the end of a session.

How onabotulinumtoxinA works and where it fits in practice

The toxin blocks acetylcholine release at the nerve terminal. Less acetylcholine reaches the muscle, so the treated muscle contracts with less force. The same mechanism acts on cholinergic nerves that supply sweat glands and the bladder detrusor, which is why the labeled uses span neurology, urology and dermatology.

Effects are local and temporary. Onset is typically a few days after injection, with the clinical effect building over one to two weeks. Function returns as nerve terminals recover, so treatment is planned as a repeating cycle rather than a one-time procedure. Accurate muscle selection and injection depth matter more than total units, which is why the labeling restricts use to clinicians trained in the relevant anatomy and injection technique.

Labeled uses and treatment context

According to FDA labeling, Botox® is approved in adults for the prevention of headaches in chronic migraine (15 or more headache days per month), cervical dystonia, blepharospasm and strabismus, severe primary axillary hyperhidrosis inadequately managed with topical agents, overactive bladder with urge incontinence when an anticholinergic is not tolerated or not effective, and detrusor overactivity associated with a neurologic condition. Upper and lower limb spasticity are also labeled indications, with pediatric use covered for spasticity and certain other indications under the current labeling.

Botox® Cosmetic is a separate presentation with its own labeling for temporary improvement of glabellar lines, lateral canthal lines and forehead lines. Do not treat the two as interchangeable stock. Any use outside the approved labeling for the product you hold is off-label, and that decision sits with the treating clinician and should be documented as such. Episodic migraine is not a labeled indication for this product.

Patient selection, contraindications and precautions

FDA labeling carries a boxed warning for distant spread of toxin effect. Symptoms such as asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulty have been reported hours to weeks after injection. Swallowing and breathing problems can be life-threatening, and deaths have been reported, most often in children treated for spasticity. Counsel patients and caregivers to seek urgent care if these symptoms appear.

Screen before every treatment, not only at the first visit:

• Known hypersensitivity to any botulinum toxin preparation or to any component of the formulation is a contraindication.
• Infection at the proposed injection site is a contraindication.
• For intradetrusor use, labeling contraindicates treatment in patients with a urinary tract infection or acute urinary retention who are not routinely catheterizing.
• Pre-existing neuromuscular disease, including myasthenia gravis, Lambert-Eaton syndrome, ALS or motor neuropathy, raises the risk of clinically significant systemic effects.
• Pre-existing swallowing or breathing difficulty increases risk, particularly when treating cervical dystonia.
• Aminoglycosides and other agents that interfere with neuromuscular transmission may potentiate the toxin’s effect.
• Anticoagulant therapy and bleeding risk should be reviewed before deep or multi-site injection.

Common adverse reactions vary by indication and injection site, and include injection-site pain and bruising, headache, neck pain, muscle weakness near the treated area, eyelid ptosis in facial injection, dysphagia in cervical dystonia, and urinary tract infection or elevated post-void residual urine after intradetrusor injection. Keep epinephrine and airway support available for hypersensitivity reactions, and advise patients to report new weakness, vision change or swallowing difficulty promptly. Patients treated for bladder indications may need post-void residual monitoring and should be prepared for intermittent catheterization if retention occurs.

Reconstitution, receiving checks and documentation

FDA labeling directs reconstitution with sterile, preservative-free 0.9% Sodium Chloride Injection, USP. The final concentration depends on the diluent volume added, and the labeled dilution tables differ by indication, so confirm the volume against the indication you are treating. Draw up using aseptic technique, rotate the vial gently rather than shaking it, and inspect the solution before use.

Build a short receiving routine for every delivery:

• Confirm cold-chain condition on arrival and move unopened vials straight to refrigerated storage.
• Check lot number, expiry date and vial strength against the packing documentation.
• Record lot and expiry in the patient chart at the time of treatment, as labeling advises for traceability.
• Rotate stock by expiry date so short-dated vials are used first.
• Follow labeling for reconstituted product, which is stored refrigerated at 2°C to 8°C and administered within 24 hours.
• Inactivate spilled toxin with dilute sodium hypochlorite solution, as described in the labeling, and dispose of vials and sharps under your local medical waste rules.

Keep a reconstitution log in the treatment room. Noting diluent volume, time of reconstitution and total units drawn gives your team a clean record if a patient asks about dose at a later visit.

Treatment intervals and what patients can expect

Retreatment intervals are set by the labeling for each indication. For chronic migraine prevention, labeling describes treatment every 12 weeks. Other indications carry their own minimum intervals, and labeling advises against treating more frequently than specified because shorter cycles may raise the chance of neutralizing antibody formation and reduced response.

Tell patients that effect builds over days, peaks in the following weeks, then fades gradually. Duration is indication-dependent and varies between individuals. A partial response at the first cycle does not always predict the next, and documenting baseline measures, such as headache days or sweat severity scores, makes the second visit easier to judge.

How Botox compares with other botulinum toxin products

Several botulinum toxin products are available to clinics, including abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA and daxibotulinumtoxinA. FDA labeling is explicit that potency units are specific to each preparation and cannot be converted between products. Never apply a conversion ratio to your Botox® protocol.

Practical differences also sit in approved indications, diluent instructions, storage temperature and whether the vial requires refrigeration before reconstitution. These are selection factors, not quality rankings. Choose the product whose labeling covers the indication you treat, then keep protocols, order sheets and consent forms product-specific so staff do not transfer units from one brand sheet to another.

Ordering for clinic and hospital use

Ordering is limited to licensed clinicians, medical practices, med spas under medical direction, and hospital purchasing teams. Professional account verification and clinic documentation requirements may apply before an order is released, and we may review order details to confirm the vial strength and quantity requested. Products are supplied through licensed pharmaceutical channels.

Med Wholesale Supplies is a wholesale supplier of aesthetic, orthopedic and medical products to clinics, hospitals and medical professionals, operating since 2013. Plan quantities against your clinic calendar: refrigerated storage space, expiry dates and the single-dose nature of each vial all limit how far ahead it makes sense to stock a Botox vial order.

Quick tip: Confirm who on staff is trained to reconstitute and document toxin before the first delivery arrives.

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.